Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients with a small abdominal aortic aneurysm and mild to moderate hypertension on aneurysmal FDG-uptake as measured with FDG PET.

Next Previous
Trial Profile

An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients with a small abdominal aortic aneurysm and mild to moderate hypertension on aneurysmal FDG-uptake as measured with FDG PET.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Acronyms PISA

Most Recent Events

  • 08 Dec 2014 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
  • 31 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01425242).
  • 26 Aug 2011 Planned end date changed from 14 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top